OBIO Highlights Long-Term Durability Of AVIM Therapy In Major Clinical Publications And HRX 2025 Presentation

Author: Benzinga Newsdesk | September 22, 2025 09:10am

Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025 | Fellow Shareholders: Recent clinical announcements related to our AVIM therapy program address three primary questions: 1. How does AVIM therapy impact blood pressure and cardiovascular function over time? 2. Is the effect durable and programmable over the long term? 3. How does can this novel therapy fit into clinical practice in the future? The August 14 publication in JACC: Advances focused on echocardiographic measures of cardiac function in patients with diastolic dysfunction. The later August publication in JACC: Clinical Electrophysiology analyzed the positive impact of AVIM therapy on blood pressure and cardiac hemodynamics using invasive and noninvasive pressure–volume (PV) loop measurements, considered by many to be the "gold standard" for comprehensive assessment of the activity of the heart. These AVIM therapy results were also assessed using standard pacing lead placement as well as lead placements intended to achieve conduction system pacing in the same patients. Conduction system pacing is a more advanced approach to cardiac pacing that is considered potentially safer and more effective and is rapidly being adopted by electrophysiologists. Most recently, our team presented data from a long-term washout study at the HRX Live 2025 Meeting ("HRX"), along with a summary of the technology simultaneously published in the peer-reviewed Heart Rhythm O2 journal.

Posted In: OBIO